AstraZeneca says the approval strengthens its push to bring immunotherapy earlier into cancer treatment, where long-term cures are possible
Previously, Arexvy was authorized for adults 60 and older, and for those 50–59 with heightened risk
Under the agreement, healthcare professionals in the country will gain access to C2N’s PrecivityAD2 blood test
The trial will enroll up to 42 patients in Finland across four cohorts
There are limited treatment options available for patients living with non-diabetic CKD, and the unmet need is high for new treatments to delay kidney disease progression and reduce cardiovascular risk
Desidustat tablets are a novel oral HIF-PHI approved for treating anaemia in non-dialysis adult CKD patients
Lilly has long voiced concerns over mass-compounded knockoffs of its tirzepatide medicines, Mounjaro and Zepbound
The move comes as China rapidly expands its capabilities in the pharmaceutical sector, particularly in licensing and drug development
The Phase 1 dose-escalation trial enrolled 25 evaluable patients and was designed to determine the recommended dose of LYMPHIR
The initiative will focus on creating healthier early-life environments, promoting physical activity, identifying risks early, and strengthening preparedness within primary health care systems
Subscribe To Our Newsletter & Stay Updated
